{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:50:21Z","timestamp":1768261821471,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund und Zielsetzung<\/jats:title>\n                <jats:p>Unter dem Begriff der mit antineutrophilen zytoplasmatischen Antik\u00f6rpern (ANCA) assoziierten Vaskulitis (AAV) wird eine Gruppe seltener, chronischer, durch rezidivierende systemische Entz\u00fcndungen gekennzeichneter Autoimmunerkrankungen mit vielf\u00e4ltigen Morbidit\u00e4ten zusammengefasst. Patienten mit AAV leiden unter diversen Organmanifestationen und schweren Nebenwirkungen der Therapie. In dieser retrospektiven Studie wurde die konkrete Belastung der Patienten durch die AAV-Erkrankung in Deutschland untersucht.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodik<\/jats:title>\n                <jats:p>Basierend auf anonymisierten L\u00e4ngsschnittdaten der gesetzlichen Krankenversicherung (GKV) zur medizinischen Versorgung zwischen 2013 und 2016 wurden aus einer repr\u00e4sentativen Kohorte von etwa 3\u202fMio. Versicherten Patienten mit Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA) identifiziert und ausgew\u00e4hlte klinische Aspekte systematisch analysiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die h\u00e4ufigsten begleitenden Morbidit\u00e4ten von GPA und MPA waren Nieren- und Atemwegserkrankungen. Eine schwere Nierenbeteiligung trat bei 11,6\u202f% der GPA- und 24,3\u202f% der MPA-Patienten innerhalb von 15\u00a0Quartalen nach der Diagnose auf. Bei einem Drittel der Patienten mit AAV entwickelten sich innerhalb der ersten 3\u00a0Quartale nach Diagnose schwere Infektionen. Die Rate der schweren Rezidive betrug j\u00e4hrlich 5\u20138\u202f%. Patienten mit AAV und Nierenbeteiligung oder Infektionen zeigten zudem eine hohe j\u00e4hrliche Mortalit\u00e4tsrate von 14,4\u202f% bzw. 5,6\u202f%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Anhand dieser Analyse deutscher Versorgungsdaten wurden krankheitsspezifische Annahmen der Belastung von Patienten mit AAV best\u00e4tigt und f\u00fcr den deutschen Kontext konkretisiert. Patienten mit AAV leiden unter einer hohen Morbidit\u00e4tsbelastung, einschlie\u00dflich multipler Krankheitsmanifestationen, Rezidiven und schwerer Komplikationen aufgrund der AAV-Therapie.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00108-021-01181-z","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T09:58:42Z","timestamp":1634637522000},"page":"210-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hohe Krankheitslast bei Patienten mit ANCA-assoziierter Vaskulitis","High burden of disease in patients with ANCA-associated vasculitis"],"prefix":"10.1007","volume":"63","author":[{"given":"H. G.","family":"Haller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"von Vietinghoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Spearpoint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Deichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Sch\u00f6nermark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"G\u00f6tte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"1181_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn\u00a0F, Walker\u00a0J (2016) Characteristics and external validity of the German health risk institute (HRI) database. Pharmacoepidemiol Drug Saf 25:106\u2013109","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1181_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth\u00a0AD, Almond\u00a0MK, Burns\u00a0A et al (2003) Outcome of ANCA-associated renal vasculitis: a\u00a05-year retrospective study. Am J Kidney Dis 41:776\u2013784","journal-title":"Am J Kidney Dis"},{"key":"1181_CR3","doi-asserted-by":"publisher","first-page":"e000435","DOI":"10.1136\/rmdopen-2017-000435","volume":"3","author":"C Heijl","year":"2017","unstructured":"Heijl\u00a0C, Mohammad\u00a0AJ, Westman\u00a0K et al (2017) Long-term patient survival in a\u00a0Swedish population-based cohort of patients with ANCA-associated vasculitis. RMD Open 3:e435","journal-title":"RMD Open"},{"key":"1181_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00393-019-0632-9","volume":"78","author":"B Hellmich","year":"2019","unstructured":"Hellmich\u00a0B (2019) ANCA-associated vasculitides: state of the art. Z\u00a0Rheumatol 78:518\u2013528","journal-title":"Z Rheumatol"},{"key":"1181_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00393-016-0223-y","volume":"76","author":"B Hellmich","year":"2017","unstructured":"Hellmich\u00a0B (2017) Current guidelines on ANCA-associated vasculitides: common features and differences. Z\u00a0Rheumatol 76:133\u2013142","journal-title":"Z Rheumatol"},{"key":"1181_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/rheumatology\/ket440","volume":"53","author":"K Herlyn","year":"2014","unstructured":"Herlyn\u00a0K, Buckert\u00a0F, Gross\u00a0WL et al (2014) Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology 53:882\u2013889","journal-title":"Rheumatology"},{"key":"1181_CR7","doi-asserted-by":"publisher","first-page":"m1070","DOI":"10.1136\/bmj.m1070","volume":"369","author":"RW Hunter","year":"2020","unstructured":"Hunter\u00a0RW, Welsh\u00a0N, Farrah\u00a0TE et\u00a0al (2020) ANCA associated vasculitis. BMJ 369:m1070","journal-title":"BMJ"},{"issue":"9","key":"1181_CR8","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DR Jayne","year":"2017","unstructured":"Jayne\u00a0DR, Bruchfeld\u00a0AN, Harper\u00a0L et al (2017) Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J\u00a0Am Soc Nephrol 28(9):2756\u20132767","journal-title":"J Am Soc Nephrol"},{"key":"1181_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA et\u00a0al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"1181_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healthpol.2016.01.007","volume":"120","author":"K Kreis","year":"2016","unstructured":"Kreis\u00a0K, Neubauer\u00a0S, Klora\u00a0M et\u00a0al (2016) Status and perspectives of claims data analyses in Germany\u2014a systematic review. Health Policy 120:213\u2013226","journal-title":"Health Policy"},{"key":"1181_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3389\/fimmu.2018.00680","volume":"9","author":"P Lamprecht","year":"2018","unstructured":"Lamprecht\u00a0P, Kerstein\u00a0A, Klapa\u00a0S et al (2018) Pathogenetic and clinical aspects of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Front Immunol 9:680","journal-title":"Front Immunol"},{"key":"1181_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little\u00a0MA, Nightingale\u00a0P, Verburgh\u00a0CA et\u00a0al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036\u20131043","journal-title":"Ann Rheum Dis"},{"key":"1181_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ndt\/gfv045","volume":"30","author":"JG Mcgregor","year":"2015","unstructured":"Mcgregor\u00a0JG, Negrete-Lopez\u00a0R, Poulton\u00a0CJ et al (2015) Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 30:171\u2013181","journal-title":"Nephrol Dial Transplant"},{"key":"1181_CR14","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/art.39104","volume":"67","author":"EM Miloslavsky","year":"2015","unstructured":"Miloslavsky\u00a0EM, Specks\u00a0U, Merkel\u00a0PA et al (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol 67:1629\u20131636","journal-title":"Arthritis Rheumatol"},{"key":"1181_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fpubh.2018.00138","volume":"6","author":"F Peters","year":"2018","unstructured":"Peters\u00a0F, Westphal\u00a0C, Kramer\u00a0A et\u00a0al (2018) Is the rise in the prevalence of renal replacement therapy at older ages the price for living longer? Front Public Health 6:138","journal-title":"Front Public Health"},{"key":"1181_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/art.20928","volume":"53","author":"E Reinhold-Keller","year":"2005","unstructured":"Reinhold-Keller\u00a0E, Herlyn\u00a0K, Wagner-Bastmeyer\u00a0R et al (2005) Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53:93\u201399","journal-title":"Arthritis Rheum"},{"key":"1181_CR17","doi-asserted-by":"publisher","first-page":"6369814","DOI":"10.1155\/2018\/6369814","volume":"2018","author":"A Salmela","year":"2018","unstructured":"Salmela\u00a0A, Tornroth\u00a0T, Poussa\u00a0T et al (2018) Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: a clinical long-term follow-up study. Int J Nephrol 2018:6369814","journal-title":"Int J Nephrol"},{"key":"1181_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, de Groot\u00a0K et al (2017) S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z\u00a0Rheumatol 76:77\u2013104","journal-title":"Z Rheumatol"},{"key":"1181_CR19","volume-title":"Gesundheit: Tiefgegliederte Diagnosedaten der Krankenhauspatientinnen und -patienten 2017","author":"Statistisches Bundesamt","year":"2018","unstructured":"Statistisches Bundesamt (2018) Gesundheit: Tiefgegliederte Diagnosedaten der Krankenhauspatientinnen und -patienten 2017"},{"key":"1181_CR20","volume-title":"Sterbef\u00e4lle \u2013 Fallzahlen nach Tagen, Wochen, Monaten, Altersgruppen und Bundesl\u00e4ndern f\u00fcr Deutschland 2016\u20132020","author":"Statistisches Bundesamt","year":"2020","unstructured":"Statistisches Bundesamt (2020) Sterbef\u00e4lle \u2013 Fallzahlen nach Tagen, Wochen, Monaten, Altersgruppen und Bundesl\u00e4ndern f\u00fcr Deutschland 2016\u20132020"},{"key":"1181_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh\u00a0M, Flossmann\u00a0O, Berden\u00a0A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542\u2013548","journal-title":"Arthritis Rheum"},{"key":"1181_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N\u00a0Engl J Med 382:622\u2013631","journal-title":"N Engl J Med"},{"key":"1181_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/acr.20471","volume":"63","author":"M Walsh","year":"2011","unstructured":"Walsh\u00a0M, Mukhtyar\u00a0C, Mahr\u00a0A et al (2011) Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 63:1055\u20131061","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1181_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","volume":"2","author":"EW Walton","year":"1958","unstructured":"Walton\u00a0EW (1958) Giant-cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis). Br Med\u00a0J 2:265\u2013270","journal-title":"Br Med J"},{"key":"1181_CR25","first-page":"1439","volume":"56","author":"RA Watts","year":"2017","unstructured":"Watts\u00a0RA, Robson\u00a0J, Pearce\u00a0F (2017) The global burden of anti-neutrophil cytoplasmic antibody vasculitis: high but unquantified. Rheumatology (oxford) 56:1439\u20131440","journal-title":"Rheumatology (oxford)"},{"key":"1181_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N\u00a0Engl J Med 352:351\u2013361","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01181-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01181-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01181-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:06:34Z","timestamp":1643886394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01181-z"}},"subtitle":["Versorgungsdatenstudie in Deutschland","A\u00a0claims data study in Germany"],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01181-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"17 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.G.\u00a0Haller war Vorsitzender eines durch Vifor unterst\u00fctzten Satellitensymposiums. S.\u00a0von Vietinghoff nahm an einem Advisory-Board-Meeting von Vifor teil. P.\u00a0Spearpoint, P.\u00a0Rutherford und D.\u00a0G\u00f6tte sind Mitarbeiter von Vifor Fresenius Medical Care Renal Pharma Ltd., Glattbrugg, Schweiz. A.\u00a0Deichmann, I.\u00a0Buchholz und M.P.\u00a0Sch\u00f6nermark sind Mitarbeiter der SKC Beratungsgesellschaft mbH, Hannover.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag enth\u00e4lt keine prim\u00e4ren Patientendaten oder Daten aus Tierversuchen. F\u00fcr die statistische Auswertung wurden anonymisierte Versorgungsdaten verwendet. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}